Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net uptake rate for accurate quantification

Journal of Nuclear Medicine

Volumn 55, Issue 2, 2014, Pages 204-210

  Velikyan, Irina ^a,b   Sundin, Anders ^b,c   Sörensen, Jens ^a,b   Lubberink, Mark ^a,b   Sandström, Mattias ^a,b   Garske Román, Ulrike ^a   Lundqvist, Hans ^a   Granberg, Dan ^b   Eriksson, Barbro ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Neuroendocrine tumor; PET; Somatostatin

Indexed keywords

DIAGNOSTIC AGENT; GALLIUM DOTATATE GA 68; GALLIUM DOTATOC GA 68; LUTETIUM DOTATATE LU 177; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TRACER; UNCLASSIFIED DRUG; 68GA DOTATATE; 68GA-DOTATATE; DRUG DERIVATIVE; GA(III) DOTATOC; GA(III)-DOTATOC; GALLIUM 68; OCTREOTIDE; ORGANOMETALLIC COMPOUND; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; MALE; MEASUREMENT ACCURACY; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NET UPTAKE RATE; PATIENT SELECTION; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; SCHOOL CHILD; STANDARDIZED UPTAKE VALUE; TUMOR DIAGNOSIS; TUMOR VOLUME; VALIDATION STUDY; WHOLE BODY IMAGING; YOUNG ADULT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; LIVER; METHODOLOGY; NEUROENDOCRINE TUMOR; PATHOLOGY; PET; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIATION DOSE; RADIOMETRY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT OUTCOME; [68GA]GA-DOTA-TATE; [68GA]GA-DOTA-TOC;

68GA; NEUROENDOCRINE TUMOR; PET; SOMATOSTATIN; [68GA]GA-DOTA-TATE; [68GA]GA-DOTA-TOC;

ADULT; AGED; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIATION DOSAGE; RADIOMETRY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84897932794     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.126177     Document Type: Article

References (34)

1. Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy -The Bad Berka experience. Theranostics. 2012;2: 437-447.
2. Al-Nahhas A. Nuclear medicine imaging of neuroendocrine tumours. Clin Med. 2012;12: 377-380.
3. Öberg K. Gallium-68 somatostatin receptor PET/CT: is it time to replace 111indium DTPA octreotide for patients with neuroendocrine tumors? Endocrine. 2012;42: 3-4.
4. 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39: 72-82.
5. 18F-FDG. Cancer. 2008;112: 2447-2455.
6. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35: 1431-1438.
7. 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38: 865-873.
8. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13: 769-775.
9. 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51: 875-882.
10. 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50: 1214-1221.
11. 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252: 850-856.
12. Versari A, Camellini L, Carlinfante G, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med. 2010;35: 321-328.
13. Van Riet J, Rattat D, Verbruggen A, Mortelmans L, Mottaghy FM. Ga-68 DOTATOC PET/CT changed the therapeutic course of a patient with the sudden onset of vision problems. Clin Nucl Med. 2009;34: 27-28.
14. Froeling V, Elgeti F, Maurer MH, et al. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann Nucl Med. 2012;26: 738-743.
15. 68Ga]Ga-based imaging agents: chemistry and diversity. Med Chem. 2011;7: 345-379.
16. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-Analysis. Endocrine. 2012;42: 80-87.
17. 68Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging. 2012;39(suppl 1): S61-S67.
18. 177Lu- DOTA-octreotate treatment. J Nucl Med. 2013;54: 33-41.
19. 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39: 50-56.
20. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl 1): 172S-178S.
21. 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54: 1755-1759.
22. 68Gabioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15: 554-560.
23. Velikyan I, Xu H, Nair M, Hall H. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Nucl Med Biol. 2012;39: 628-639.
24. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35: 2320-2333.
25. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-To-brain transfer constants from multiple-Time uptake data. J Cereb Blood Flow Metab. 1983;3: 1-7.
26. Reubi JC, Schär J-C, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27: 273-282.
27. 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52: 1864-1870.
28. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31: 1257-1262.
29. 177Lu-DOTA0,Tyr3] octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33: 1346-1351.
30. 68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours: impact of peptide mass. Nucl Med Biol. 2010;37: 265-275.
31. 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51: 353-359.
32. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51: 1349-1356.
33. 68Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011;52: 1679-1683.
34. 68Ga-DOTA-Tyr3- octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50: 1427-1434.